Drug | Phenotypically resistant | Phenotypically susceptible | Performancesb | |||||||
---|---|---|---|---|---|---|---|---|---|---|
RAVa | Total | RAVa | Total | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | |||
Present | Absent | Present | Absent | |||||||
Rifampicin | 1688 | 73 | 1761 | 93 | 3315 | 3408 | 95.9% (94.8%-96.7%) | 97.3% (96.7%-97.8%) | 94.8% (93.7%-95.7%) | 97.9% (97.3%-98.3%) |
Isoniazid | 1827 | 181 | 2008 | 71 | 3075 | 3146 | 91.0% (89.7%-92.2%) | 97.7% (97.2%-98.2%) | 96.3% (95.3%-97.0%) | 94.4% (93.7%-95.1%) |
Ethambutol | 998 | 112 | 1110 | 284 | 3201 | 3485 | 89.9% (88.0%-91.6%) | 91.9% (90.9%-92.7%) | 77.9% (75.8%-79.7%) | 96.6% (96.0%-97.2%) |
Pyrazinamide | 747 | 191 | 938 | 89 | 2276 | 2365 | 79.6% (76.9%-82.2%) | 96.2% (95.4%-97.0%) | 89.4% (87.2%-91.2%) | 92.3% (91.3%-93.1%) |
Levofloxacin | 53 | 1 | 54 | 2 | 48 | 50 | 98.2% (90.1%-100.0%) | 96.0% (86.3%-99.5%) | 96.4% (87.2%-99.0%) | 98.0% (87.3%-99.7%) |
Moxifloxacin | 137 | 13 | 150 | 118 | 560 | 678 | 91.3% (85.6%-95.3%) | 82.6% (79.5%-85.4%) | 53.7% (49.5%-58.0%) | 97.7% (96.2%-98.6%) |
Amikacin | 213 | 45 | 258 | 14 | 1042 | 1056 | 82.6% (77.4%-87.0%) | 98.7% (97.8%-99.3%) | 93.8% (90.0%-96.3%) | 95.9% (94.7%-96.8%) |
Capreomycin | 200 | 67 | 267 | 42 | 1104 | 1146 | 74.9% (69.3%-80.0%) | 96.3% (95.1%-97.4%) | 82.6% (77.8%-86.6%) | 94.3% (93.1%-95.3%) |
Kanamycin | 465 | 39 | 504 | 25 | 1129 | 1154 | 92.3% (89.6%-94.4%) | 97.8% (96.8%-98.6%) | 94.9% (92.7%-96.5%) | 96.7% (95.5%-97.5%) |
Streptomycin | 762 | 216 | 978 | 110 | 2176 | 2286 | 77.9% (75.2%-80.5%) | 95.2% (94.2%-96.0%) | 87.4% (85.2%-89.3%) | 91.0% (90.0%-91.9%) |
Ethionamide | 280 | 73 | 353 | 158 | 611 | 769 | 79.3% (74.7%-83.4%) | 79.5% (76.4%-82.3%) | 63.9% (60.4%-67.3%) | 89.3% (87.2%-91.2%) |